NOW AVAILABLE: For the Lung Cancer Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.
Of the large number of brands analyzed for the lung cancer market, Merck’s Keytruda produced the highest percentage of the promotional volume during 2016, launching the “KEY+YOU” support program, and announcing a new expanded indication for Keytruda. Bristol-Myers Squibb promoted Opdivo’s “240 mg flat dose” for NSCLC, RCC, and Melanoma indications. Medimmune circulated unbranded durvalumab promotions noting that “PD-L1 pathway inhibition offers a new foundation for immunotherapy combination research”. Testing for genetic mutations at disease progression remained a priority topic with FDA-approved, companion diagnostic tests for Tagrisso and Tarceva. Multiple brands launched new campaign themes, including Abraxane, Alecensa, Iressa, Keytruda, Opdivo, Portrazza, Tagrisso, and Xalkori. Overall, materials mostly targeted healthcare professionals and support messages were prioritized. Additional insights into marketing strategies and channel utilization are available with a subscription.
Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.Reports are available by annual subscription for over 50 primary and specialty markets.
For more information please contact:
US Markets: Christine Alongi at Alongi@dtwresearch.com
Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com